Here is a synopsis of why VLTR and DAL have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:
Volterra Semiconductor Corporation (VLTR<
/a>) reported fourth-quarter earnings per share of 13
cents on January 24, which came in 2 cents shy of the
Zacks Consensus Estimate. The full-year average forecast
dipped 6 cents to 89 cents per share in the last 7 days as
10 out of the 12 covering analysts lowered expectations.
Next year?s estimate dropped 11 cents to $1.44 per share
in the same time span.
Delta Air Lines, Inc.?s (DAL) fourth -quarter earnings of 19 cents per share,
announced on January 18, lagged the Zacks Consensus
Estimate by 6 cents. The average forecast for 2011
decreased 17 cents to a profit of $2.08 per share in the
last 30 days. During that time period, the following
year?s estimate moved down 9 cents to $2.23 per share.
Here is a synopsis of why VRUS and FMS have a Zacks Rank
of 4 (Sell) and should also most likely be sold or avoided
for the next one to three months. Note that a #4 Sell
rating is applied to 15% of all the stocks ranked by
Zacks;
Pharmasset, Inc. (VRUS<
/a>) posted a fourth-quarter loss of 59 cents per share on
November 23 while analysts projected a loss of 45 cents.
The Zacks Consensus Estimate for the current year is
pegged at a loss of $2.02 per share, a decline of 6 cents
in the last 30 days. The average forecast for 2012 slid
down 6 cents to a loss of $2.25 per share.
Fresenius Medical Care AG & Co. (FMS) announced a third-quarter profit of 82 cents per share
on November 2, which missed the analysts? estimates by a
penny. The Zacks Consensus Estimate for the full year
decreased by a penny to $3.23 per share over the past 60
days as the covering analysts reduced expectations.
Estimates of 2011 also fell by a penny in a span of a week
to $3.52 per share.
DELTA AIR LINES (DAL): Free Stock Analysis Report
FRESENIUS MED (FMS): Free Stock Analysis Report
VOLTERRA SEMI (VLTR): Free Stock Analysis Report
PHARMASSET INC (VRUS): Free Stock Analysis Report
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.